Antiplatelet medicines after left atrial closure in dialysis patients
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial looks at the best blood-thinning (antiplatelet) plan after a left atrial appendage closure procedure in people with kidney failure on dialysis. It may help reduce stroke risk while also lowering medicine-related side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a successful left atrial appendage closure with an Amplatzer or WATCHMAN device within the last 37 days
- You have end-stage kidney disease and receive ongoing dialysis (hemodialysis or peritoneal dialysis)
- You are age 18 or older
- You agree to follow the study visits and the randomized antiplatelet medicine plan
- You can and will sign the study consent form
- If you are pregnant, breastfeeding, or could become pregnant, you must agree to required birth-control steps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares which two medicines work best after a device closes off a part of the heart called the left atrial appendage. It may help reduce stroke risk while balancing bleeding risk after your procedure.
This study is testing a minimally invasive procedure to close off a part of the heart (the left atrial appendage) in people with kidney failure on dialysis who also have atrial fibrillation. The goal is to reduce the risk of stroke without needing long-term blood thinners.
This trial studies a “double anti-platelet” medicine plan (aspirin plus clopidogrel) after closing the left atrial appendage, a procedure used to reduce stroke risk in some heart rhythm conditions. It aims to find a safer, better medicine strategy for people who cannot take standard blood thinners.
This trial tests whether patients who receive a special device to close a hole in the heart (to prevent stroke from irregular heartbeat) can safely take fewer blood-thinning medications afterward. The study compares taking a standard blood thinner for 3 months versus taking aspirin only, to see which approach works best with fewer bleeding risks.
This trial tests whether it is safe for patients with atrial fibrillation to stop taking blood thinners after they have had heart surgery, including closure of the left atrial appendage. The goal is to see if these patients can avoid long-term medication without increasing the risk of stroke.
This study looks at whether a lower-dose blood thinner works as well as the usual recommended anti-clot treatment after a procedure that closes off the heart’s left atrial appendage. It may help reduce bleeding risk while still preventing dangerous blood clots.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.